Klinikum Oldenburg
Klinikum Oldenburg
Oldenburg, Germany14 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| First-line Treatment in Locally Advanced or Metastastic Small Bowel Adenocarcinoma | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, metastatic neoplasm, neoplasm | Not yet recruiting | Phase 2 | 2026-09-28 | NCT07844057 | |
| A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2) | Plaque Psoriasis | Active, not recruiting | Phase 3 | 2026-09-28 | NCT06220604 | |
| A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | Active, not recruiting | Phase 3 | 2026-09-28 | NCT06095115 | |
| Shortening Treatment Duration in Uncomplicated Candidemia: the CanTEN Trial | Bacterial Infections and Mycoses, Fungemia, Infections, Inflammation, Invasive Fungal Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Sepsis, Systemic Inflammatory Response Syndrome, candidemia, candidiasis, candidiasis, invasive, fungal infectious disease | Not yet recruiting | Phase 4 | 2026-09-01 | NCT07788586 | |
| A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 3 | 2026-08-20 | NCT05197192 | |
| Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 3 | 2026-08-17 | NCT06216158 | |
| Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2026-07-30 | NCT07197307 | |
| Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) | Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 3 | 2026-04-30 | NCT04608318 | |
| Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD). | growth delay due to insulin-like growth factor type 1 deficiency | Recruiting | Not stated | 2026-02-06 | NCT00903110 | |
| International HIT-MED Registry (I-HIT-MED) | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, brain disorder, central nervous system cancer, central nervous system disorder, ependymoma, epithelial neoplasm, glioma, medulloblastoma, neoplasm, nervous system disorder, neuroepithelial neoplasm, pineal body neoplasm, primitive neuroectodermal tumor | Recruiting | Not stated | 2025-12-04 | NCT02417324 | |
| International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, brain cancer, brain disorder, central nervous system cancer, central nervous system disorder, epithelial neoplasm, glioma, medulloblastoma, neoplasm, nervous system disorder, neuroepithelial neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 2 / Phase 3 | 2025-12-04 | NCT02066220 | |
| CytOSorb TreatMent Of Critically Ill PatientS Registry | Acute-On-Chronic Liver Failure, Chemically-Induced Disorders, Digestive System Diseases, Disease Attributes, Drug Misuse, Drug Overdose, Hemic and Lymphatic Diseases, Hepatic Insufficiency, Infarction, Infections, Inflammation, Lymphohistiocytosis, Hemophagocytic, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Postoperative Complications, Postoperative Vasoplegic Syndrome, Prescription Drug Misuse, Respiration Disorders, Rhabdomyolysis, Sepsis, Shock, Shock, Cardiogenic, Systemic Inflammatory Response Syndrome, Vasoplegia, acute liver failure, adult acute respiratory distress syndrome, burn, cardiovascular disorder, cytokine release syndrome, heart disorder, histiocytosis, infectious disease, injury, ischemic disease, liver disorder, liver failure, lung disorder, lymphatic system disorder, muscle tissue disorder, musculoskeletal system disorder, myocardial infarction, myocardial ischemia, non-Langerhans cell histiocytosis, pancreas disorder, pancreatitis, psychiatric disorder, respiratory system disorder, substance-related disorder, toxic shock syndrome, vascular disorder | Recruiting | Not stated | 2025-09-11 | NCT05146336 | |
| Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasm, Residual, Neoplasms by Histologic Type, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Recurrence, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2025-07-25 | NCT05182385 | |
| Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | Recruiting | Phase 2 | 2025-04-29 | NCT06061094 |